Skip to main content
Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

Summary by WBOC 16
Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show

8 Articles

WBOC 16WBOC 16
+6 Reposted by 6 other sources
Center

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show

Read Full Article
stocktitan.netstocktitan.net

Skin disease trial shows 62% response at 40 weeks, no new safety signals

Up to 32% reached HiSCR100 and 25% achieved inflammatory remission in Phase 3 HS trials. MoonLake expects 52-week data in Q2 2026.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 75% of the sources are Center
75% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Globe Newswire broke the news in on Saturday, March 28, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Salisbury, Maryland icon

Salisbury, Maryland

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal